Behavioral versus pharmacological treatments of obsessive compulsive disorder: A meta-analysis

Psychopharmacology

Volumn 136, Issue 3, 1998, Pages 205-216

  Kobak, Kenneth A ^a   Greist, John H ^a   Jefferson, James W ^a   Katzelnick, David J ^a   Henk, Henry J ^a  

^a Dean Found Hlth   (United States)

Author keywords

Behavior therapy; Meta analysis; Obsessive compulsive disorder; SSRI

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

BEHAVIOR THERAPY; CLINICAL TRIAL; DRUG CHOICE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METHODOLOGY; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

BEHAVIOR THERAPY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PATIENT DROPOUTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0031937847     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050558     Document Type: Review

References (68)

1. Abramowitz J (1997) Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 65 : 44-52
2. American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, 3rd edn. APA, Washington, DC
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. APA, Washington, DC
4. Baer L, Minichiello WE (1990) Behavioral treatment for obsessive-compulsive disorder. In: Noyes R, Roth M, Burrows GD (eds) Handbook of anxiety, vol 4: the treatment of anxiety. Elsevier, Amsterdam, NY
5. Baer L, Brown-Beasley MW, Sorce J, Henriquess AI (1993) Computer-assisted telephone administration of a structured interview for obsessive-compulsive disorder. Am J Psychiatry 150 : 1737-1738
6. Bolton D, Collins S, Steinberg D (1983) The treatment of obsessive-compulsive disorder in adolescence: a report of fifteen cases. Br J Psychiatry 142 : 456-464
7. Buchanan AW, Meng KS, Marks IM (1996) What predicts improvement and compliance during the behavioral treatment of obsessive compulsive disorder? Anxiety 2 : 22-27
8. Christensen H, Hadzi-Pavlovic D, Andrews G, Mattick R (1987) Behavior therapy and tricyclic medication in the treatment of obsessive compulsive disorder: a quantitative review. J Consult Clin Psychol 55 : 701-711
9. Cleophas TJM (1993) Crossover studies: a modified analysis with more power. Clin Pharmacol Ther 53 : 515-520
10. Clomipramine Collaborative Study Group (1991) Clomipramine in the treatment of patients with obsessive-compulsive disorder, Arch Gen Psychiatry 48 : 730-738
11. Coleman HLK, Wampold BE, Casali SL (1995) Ethnic minorities' ratings of ethnically similar and European American counselors: a meta-analysis. J Counsel Psychol 42 : 55-64
12. Cramer H (1974) Mathematical models of statistics. Princeton University Press, Princeton, N.J.
13. Fals-Stewart W, Schafer J (1992) The treatment of substance abusers diagnosed with obsessive-compulsive disorder: an outcome study. J Subst Abuse Treat 9 : 365-370
14. Fisher S, Greenberg RP (1993) How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis 181 : 345-350
15. Flament MF, Rapoport JL, Murphy DL, Berg CJ, Lake CR (1987) Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 44 : 219-225
16. Foa EB, Steketee GS, Grayson JB, Doppelt HG (1983) Treatment of obsessive-compulsives: when do we fail? In: Foa E, Emmelkamp PMG (eds) Failures in behavior therapy. Wiley, New York
17. Foa EB, Steketee GS, Ozarow BJ (1985) Behavior therapy with obsessive-compulsives: from theory to treatment. In: Mavissakalian M, Turner SM, Michelson L (eds) Obsessive-compulsive disorder: psychological and pharmacological treatment. Plenum Press, New York, pp 49-129
18. Foa EB, Kozak MJ, Steketee GS, McCarthy PR (1992) Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behavior therapy. Br J Clin Psychol 31 : 279-292
19. Glass GV, McGaw B, Smith ML (1981) Meta-analysis in social research. Sage, Beverly Hills, Calif.
20. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heniger GR, Charney DS (1989a) Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: comparisons of fluvoxamine and desipramine. Arch Gen Psychiatry 47 : 577-585
21. Goodman WK, Price LH, Rasmussen SA (1989b) The Yale-Brown obsessive compulsive scale, I: development, use, and reliability. II. Validity. Arch Gen Psychiatry 46 : 1006-1011, 1012-1016
22. Greist JH (1989) Computer-administered behavior therapies. Int Rev Psychiatry 1 : 267-294
23. Greist JH, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen SA, White K, Sikes C (1995a) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry, 52 : 289-295
24. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC (1995b) Efficacy and tolerability of serotonin transport inhibitors in obsessive compulsive disorder: a meta-analysis. Arch Gen Psychiatry 52 : 53-60
25. Greist JH, Baer L, Marks I, Kobak KA, Wenzel KW, Dottl SL (1996) Computer-Assisted behavior therapy for OCD. American Psychiatric Association 149th Annual Meeting, New York, N.Y.
26. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology.DHEW Publication No. (ABM) 76-338. US Government Printing Office, Washington, D.C.
27. Hafner RJ, Gilchrist P, Bowling J, Kalucy R (1981) The treatment of obsessional neurosis in a family setting. Aust NZ J Psychiatry 15 : 145-151
28. Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, Orlando, Florida
29. Hewlett WA, Vinogradov S, Agras WS (1992) Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 12 : 420-430
30. Holloway EL, Wampold BE (1986) Relation between conceptual level and counseling-related tasks: a meta-analysis. J Counsel Psychol 33 : 310-319
31. Ingram IM (1961) Obsessional illness in mental hospital patients. J Ment Sci 107 : 382-402
32. Jefferson JW, Altemus M, Jenike MA, Pigott TA, Stein DJ, Greist JH (1995) Algorithm for the treatment of obsessive-compulsive disorder (OCD). Psychopharmacol Bull 31 : 487-490
33. Jenike MA, Hyman S, Baer L, Holland A, Minichiella WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J (1990) A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 147 : 1209-1215
34. Johnston H, Kobak KA, Greist JH (1990) Placebo side effects in depression and obsessive-compulsive disorder. New Research Program and Abstracts, American Psychiatric Association, 143rd Annual Meeting, New York, N.Y.
35. Katz RJ, Landau P, De Veaugh-Geiss J (1990) Response: drug versus behavioral treatment of obsessive-compulsive disorder. Biol Psychiatry 28 : 1073-1074
36. Leonard H, Swedo SE, Lenane MC, Rettew DC, Cheslow DL, Hamburger SD, Rapoport JL (1991) A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 48 : 922-927
37. Leonard H, Swedo SE, Rapoport JL, Coffey M, Cheslow D (1988) Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull 24 : 93-95
38. Liebowitz MR, Hollander E, Fairbanks J, Campeas R (1990) Fluoxetine for adolescents with obsessive-compulsive disorder. Am J Psychiatry 147 : 370-371
39. Lindsay M, Crino R, Andrews G (1997) A controlled study of exposure and response prevention in the treatment of obsessive-compulsive disorder. Br J Psychiatry 171 : 135-139
40. Lo WH (1967) A follow-up study of obsessional neurotics in Hong Kong Chinese. Br J Psychiatry 113 : 823-832
41. Malan D (1979) Individual psychotherapy and the science of psychodynamics. Butterworths, London
42. March JS, Johnston H, Jefferson JW, Kobuk KA, Greist JH (1990) Do subtle neurological impairments predict treatment resistance to clomipramine in children and adolescents with obsessive-compulsive disorder? J Child Adolesc Psychopharmacol 1 : 133-140
43. March JS, Mulle K, Herbei B (1994) Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: an open trial of a new protocol-driven treatment package. J Am Acad Child Adolesc Psychiatry 33 : 333-341
44. Marks IM (1981) Review of behavioral psychotherapy, I : Obsessive-compulsive disorders. Am J Psychiatry 138 : 584-592
45. Marks IM (1990) Drug versus behavioral treatment of obsessive-compulsive disorder. Biol Psychiatry 28 : 1065-1080
46. McDonald R, Marks IM, Blizard R (1988) Quality assurance of outcome in mental health care: a model for routine use in clinical settings. Health Trends 20 : 111-114
47. Mullen B (1989) Advanced basic meta-analysis. Lawrence Erlbaum Associates, Hillsdale, N.J.
48. Pato M, Zohar-Kadouch R, Zohar J (1988) Return of symptoms after discontinuation of clomipramine in patients with obsessive compulsive disorder. Am J Psychiatry 145 : 1521-1525
49. Piccinelli M, Pini S, Bellantuono C, Wilkinson G (1995) Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Brit J Psychiatry 166 : 424-443
50. Rachman SJ, Hodgson RJ (1980) Obsessions and compulsions. Prentice Hall, Englewood Cliffs, N.J.
51. Rasmussen SA, Eisen JL, Pato MT (1993) Current issues in the pharmacologic management of obsessive compulsive disorder. J Clin Psychiatry 54[suppl 6] : 4-9
52. Rasmussen SA, Goodman WK, Greist JH, Jenike MA, Kozak MJ, Liebowitz M, Robinson DG, White K (1998) Fluvoxamine in the treatment of obsessive-compulsive disorder: a multicenter double-blind placebo controlled study in outpatients. Am J Psychiatry (in press)
53. Rauch SL, O'Sullivan RL, Jenike MA (1996) Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J Clin Psychopharmacol 16 : 81-84
54. Richelson E (1994) Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc 69 : 1069-1081
55. Rosenfeld R, Dar R, Andersen D, Kobak KA, Greist JH (1992) A computer administered version of the Yale-Brown Obsessive Compulsive Scale. Psychol Assess 4 : 329-332
56. Rosenthal R (1979) The "file-drawer" problem and tolerance for null results. Psychol Bull 86 : 638-641
57. Rosenthal R (1991) Meta-analytic procedures for social research (revised ed). Sage, Newbury Park, Calif.
58. Salkovskis PM, Westbrook D (1989) Behaviour therapy and obsessional ruminations: can failure be turned into success? Behav Res Ther 27 : 149-160
59. Stein DJ, Spadaccini E, Hollander E (1995) Meta-analysis of pharmaeotherapy trials of obsessive-compulsive disorder. Int Clin Psychopharmacol 10 : 11-18
60. Steiner M, Bushnell MS, Gergel IP (1995) Long-term treatment and prevention of relapse of OCD with paroxetine. Paper presented at the 148th Annual Meeting of the American Psychological Association, New York
61. Steketee GS (1993) Treatment of obsessive compulsive disorder. Guilford, New York
62. Stevens J (1986) Applied multivariate statistics for the social sciences. Erlbaum, Hillsdale, N.J.
63. Strube MJ, Gardner W, Hartmann DP (1985) Limitations, liabilities, and obstacles in reviews of the literature: the current status of meta-analysis. Clin Psychol Rev 5 : 63-78
64. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominquez RA, Koran LM, Shear MK, Goodman WK, Genduso LA (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51 : 559-567
65. Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM (1992) Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 161 : 665-670
66. van Balkom AJLM, van Oppen P, Vermeulen AWA, van Dyck R, Nauta MCE, Vorst HCM (1994) A meta-analysis of the treatment of obsessive compulsive disorder: a comparison of antidepressants, behavior. and cognitive therapy. Clin Psychol Rev 14 : 359-381
67. Wheadon DE, Bushnell WD, Steiner M (1993) A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. Paper presented at the Annual Meeting of the American College of Neuropsycho-pharmacology, Honolulu, Hawaii
68. Yaryura-Tobias JA, Neziroglu FA, McKay DR (1994) The action of venlafaxine on obsessive-compulsive disorder. Biol Psychiatry 35 : 737